Literature DB >> 10090743

Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity.

M M Pallitto1, J Ghanta, P Heinzelman, L L Kiessling, R M Murphy.   

Abstract

beta-Amyloid (Abeta), the primary protein component of Alzheimer's plaques, is neurotoxic when aggregated into fibrils. We have devised a modular strategy for generating compounds that inhibit Abeta toxicity, based on linking a recognition element for Abeta to a disrupting element designed to interfere with Abeta aggregation. One such compound, with the 15-25 sequence of Abeta as the recognition element and a lysine hexamer as the disrupting element, altered Abeta aggregation kinetics and protected cells from Abeta toxicity [Ghanta et al. (1996) J. Biol. Chem. 271, 29525]. To optimize the recognition element, peptides of 4-8 residues composed of overlapping sequences within the 15-25 domain were synthesized, along with hybrid compounds containing those recognition sequences coupled to a lysine hexamer. None of the recognition peptides altered Abeta aggregation kinetics and only two, KLVFF and KLVF, had any protective effect against Abeta toxicity. The hybrid peptide KLVFF-KKKKKK dramatically altered Abeta aggregation kinetics and aggregate morphology and provided significantly improved protection against Abeta toxicity compared to the recognition peptide alone. In contrast, FAEDVG-KKKKKK possessed only modest inhibitory activity and had no marked effect on Abeta aggregation. The scrambled sequence VLFKF was nearly as effective a recognition domain as KLVFF, suggesting the hydrophobic characteristics of the recognition sequence are critical. None of the cytoprotective peptides prevented Abeta aggregation; rather, they increased aggregate size and altered aggregate morphology. These results suggest that coupling recognition with disrupting elements is an effective generalizable strategy for the creation of Abeta inhibitors. Significantly, prevention of Abeta aggregation may not be required for prevention of toxicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10090743     DOI: 10.1021/bi982119e

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  45 in total

1.  Measurements of residual dipolar couplings in peptide inhibitors weakly aligned by transient binding to peptide amyloid fibrils.

Authors:  Zhongjing Chen; Bernd Reif
Journal:  J Biomol NMR       Date:  2004-08       Impact factor: 2.835

2.  Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils.

Authors:  Jan Bieschke; Martin Herbst; Thomas Wiglenda; Ralf P Friedrich; Annett Boeddrich; Franziska Schiele; Daniela Kleckers; Juan Miguel Lopez del Amo; Björn A Grüning; Qinwen Wang; Michael R Schmidt; Rudi Lurz; Roger Anwyl; Sigrid Schnoegl; Marcus Fändrich; Ronald F Frank; Bernd Reif; Stefan Günther; Dominic M Walsh; Erich E Wanker
Journal:  Nat Chem Biol       Date:  2011-11-20       Impact factor: 15.040

3.  Probing the efficacy of peptide-based inhibitors against acid- and zinc-promoted oligomerization of amyloid-β peptide via single-oligomer spectroscopy.

Authors:  Lyndsey R Powell; Kyle D Dukes; Robin K Lammi
Journal:  Biophys Chem       Date:  2011-09-08       Impact factor: 2.352

4.  Effects of peptides derived from terminal modifications of the aβ central hydrophobic core on aβ fibrillization.

Authors:  Cyrus K Bett; Wilson K Serem; Krystal R Fontenot; Robert P Hammer; Jayne C Garno
Journal:  ACS Chem Neurosci       Date:  2010-08-26       Impact factor: 4.418

5.  Structure-activity relationships in peptide modulators of β-amyloid protein aggregation: variation in α,α-disubstitution results in altered aggregate size and morphology.

Authors:  Cyrus K Bett; Johnpeter N Ngunjiri; Wilson K Serem; Krystal R Fontenot; Robert P Hammer; Robin L McCarley; Jayne C Garno
Journal:  ACS Chem Neurosci       Date:  2010-07-08       Impact factor: 4.418

6.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.

Authors:  K A Conway; S J Lee; J C Rochet; T T Ding; R E Williamson; P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

7.  Hsp20, a novel alpha-crystallin, prevents Abeta fibril formation and toxicity.

Authors:  Sungmun Lee; Kenneth Carson; Allison Rice-Ficht; Theresa Good
Journal:  Protein Sci       Date:  2005-03       Impact factor: 6.725

8.  Inhibition of insulin fibrillogenesis with targeted peptides.

Authors:  Todd J Gibson; Regina M Murphy
Journal:  Protein Sci       Date:  2006-04-05       Impact factor: 6.725

Review 9.  Immunization treatment approaches in Alzheimer's and prion diseases.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

10.  Reversibility of beta-amyloid self-assembly: effects of pH and added salts assessed by fluorescence photobleaching recovery.

Authors:  Nadia J Edwin; Robert P Hammer; Robin L McCarley; Paul S Russo
Journal:  Biomacromolecules       Date:  2010-02-08       Impact factor: 6.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.